...
首页> 外文期刊>U. S. pharmacist >Emerging Treatments for Dravet and Lennox-Gastaut Syndromes
【24h】

Emerging Treatments for Dravet and Lennox-Gastaut Syndromes

机译:Dravet和Lennox-Gastaut综合征的新兴治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Dravet syndrome and Lennox-Gastaut syndrome are severe epileptic encephalopathies that manifest during early childhood. Challenging to diagnose and treat, patients often develop severe neurologic, intellectual, and behavioral disorders that progressively worsen. While multiple pharmacologic and nonpharmacologic interventions exist, careful selection of therapy is paramount as some medications can exacerbate seizures. With the recent approval of Epidiolex (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut or Dravet syndrome, providers and patients have an additional therapeutic option to consider. Within this context, pharmacists have a vital role in educating providers, caregivers, and patients on medication therapy.
机译:Dravet综合征和Lennox-gastaut综合征是在幼儿期内显现的严重癫痫脑病。 挑战诊断和治疗,患者经常发育严重的神经系统,智力和行为障碍,逐渐恶化。 虽然存在多种药理和非武装干预措施,但仔细选择治疗是至关重要的,因为一些药物可以加剧癫痫发作。 随着近期EPIDIOLEX(大麻)治疗与Lennox-Gastaut或Dravet综合征相关的癫痫发作的批准,提供者和患者有额外的治疗选择需要考虑。 在这方面,药剂师在教育提供者,照顾者和患者对药物治疗方面具有重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号